Table 4 Lipid control for the treatment

N (%)

169 (51.7%)

147 (36.1%)

65 (19.9%)

80 (19.7%)

P value

0.5800

< 0.0001

< 0.0001

< 0.0001

Sex

female

44 (44.9%)

49 (36.0%)

16 (16.3%)

24 (17.6%)

male

125 (54.6%)

98 (36.2%)

49 (21.4%)

56 (20.7%)

P value

0.1080

0.9790

0.2930

0.4700

Age (years)

< 50

41 (42.7%)

8 (21.6%)

6 (6.3%)

4 (10.8%)

50–60

52 (46.0%)

39 (30.6%)

23 (20.4%)

18 (14.2%)

> 60

76 (64.4%)

100 (41.2%)

36 (30.5%)

58 (23.9%)

P value

0.0020

0.0220

< 0.0001

0.0300

HbA1c (%)

< 7

62 (68.1%)

48 (41.4%)

35 (38.5%)

30 (25.9%)

7–10

84 (50.6%)

72 (35.0%)

24 (14.5%)

40 (19.4%)

> 10

23 (32.9%)

27 (31.8%)

6 (8.6%)

10 (11.8.%)

P value

< 0.0001

0.3310

< 0.0001

0.0450

T2DM duration (years)

< 3

27 (38.0%)

14 (26.9%)

6 (8.5%)

6 (11.5%)

3–10

69 (53.1%)

59 (43.1%)

27 (20.8%)

34 (24.8%)

> 10

73 (57.9%)

74 (33.9%)

32 (25.4%)

40 (18.3%)

P value

0.0250

0.0740

0.0160

0.0950

BMI (kg/m²)

< 24

46 (51.1%)

49 (38.9%)

21 (23.3%)

27 (21.4%)

≥ 24

123 (51.9%)

98 (34.9%)

44 (18.6%)

53 (18.9%)

P value

0.8990

0.4360

0.3350

0.5470

Hypertension

Yes

99 (62.7%)

103 (41.0%)

46 (29.1%)

59 (23.5%)

No

70 (41.4%)

44 (28.2%)

19 (11.2%)

21 (13.5%)

P value

< 0.0001

0.0090

< 0.0001

0.0130

FLD

Yes

39 (42.9%)

29 (29.6%)

10 (11.0%)

11 (11.2%)

No

130 (55.1%)

118 (38.2%)

55 (23.3%)

69 (22.3%)

P value

0.0470

0.1230

0.0120

0.0160